Abstract
Background
Monitoring changes of seroprevalence over time is important at the beginning and during of COVID-19 outbreak to anticipate its dynamics and plan an adequate public health response.
Methods
We conducted a repeated cross-sectional investigation among asymptomatic outpatient subjects and covered 0.1% of total population of Northern Serbia (Autonomous Province of Vojvodina). Each participant was tested for anti-SARS-CoV-2 antibodies using an immunochromatographic qualitative test (point-of-care rapid test). In the last round of survey IgG antibodies targeting the S1 subunit of the spike protein and the nucleocapsid protein of SARS-CoV-2 virus were assessed.
Results
During the four rounds of survey (between the end of April and the end of September), anti-SARS-CoV-2 seropositivities based on immunochromatographic test results were 2.60% (95% CI 1.80–3.63), 3.93% (95% CI 2.85–5.28), 6.11% (95% CI 4.72–7.77) and 14.60% (95% 12.51–16.89), respectively. After adjusting with results obtained from the Line immunoassay test, the estimated overall seroprevalence increased to 16.67% (95% CI 14.45–19.08) corresponding to 322,033 infections in total by the end of September 2020 in Vojvodina’s population. Throughout the course of the study, for every RT-PCR confirmed case of COVID-19, there were 39–87 additional infections in Vojvodina. No significant difference (p>0.05) in SARS-CoV-2 seropositivity regarding gender and between age subgroups was observed over the course of the survey.
Conclusions
The population prevalence of SARS-CoV-2 antibodies implies much more widespread infection in Vojvodina than indicated by the number of confirmed cases. However, our results suggest that the population of Vojvodina has not reached a desirable level of protection from SARS-CoV-2 virus by the end of September 2020.
Publisher
Public Library of Science (PLoS)
Reference34 articles.
1. WHO. Population-based age-stratified seroepidemiological investigation protocol for COVID-19 virus infection. March 17, 2020. https://apps.who.int/iris/handle/10665/331656 [accessed November 30, 2020].
2. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study;S Stringhini;Lancet,2020
3. Seroprevalence of SARS-CoV-2-Specific Antibodies Among Adults in Los Angeles County, California, on April 10–11, 2020;N Sood;JAMA,2020
4. Has China faced only a herald wave of SARS-CoV-2?;A Flahault;Lancet,2020
5. Population-based seroprevalence surveys of anti-SARS-CoV-2 antibody: An up-to-date review;CC Lai;Int J Infect Dis,2020
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献